Jardiance Side Effects: Withdrawal and Discontinuation Syndrome Explained

What "Withdrawal Syndrome" Actually Means for an SGLT2 Inhibitor

Empagliflozin does not act on opioid receptors, dopamine pathways, or GABA channels. No randomized trial or FDA label classifies it as habit-forming. The Jardiance U.S. Prescribing information does not list a withdrawal syndrome in its adverse reactions section, and the DSM-5 does not recognize an SGLT2-inhibitor use disorder.

What does happen after stopping is more accurately called a pharmacodynamic offset. Once the drug is cleared, the SGLT2 transporter in the proximal tubule resumes full glucose reabsorption. The urinary glucose excretion that averaged roughly 70 to 80 grams per day during treatment drops back toward zero within 48 to 72 hours of the last dose, and blood sugar climbs accordingly.

Why Patients and Prescribers Confuse Offset with Withdrawal

Many patients report feeling worse in the first one to two weeks after stopping empagliflozin: fatigue, increased thirst, polyuria from worsening hyperglycemia, and occasionally a transient surge in body weight from fluid retention. These symptoms track the loss of the drug's pharmacologic effects, not a neurologic dependence state. The distinction matters clinically because management differs. Dependence requires tapering; pharmacodynamic offset requires a replacement treatment plan.

What the FDA Label Actually Says About Stopping Jardiance

The FDA-approved prescribing information for Jardiance does not instruct prescribers to taper the dose before stopping. It does, however, require temporary discontinuation before surgical procedures due to the risk of euglycemic DKA, and it advises stopping the drug if eGFR falls below 30 mL/min/1.73 m² (for the type 2 diabetes indication). Both instructions imply abrupt discontinuation is clinically acceptable when medically necessary, with appropriate glucose monitoring afterward.

Blood Glucose Rebound After Stopping Empagliflozin

Glucose control deteriorates rapidly after stopping empagliflozin. This is not a side effect of the drug itself, but it is the most consequential physiologic change patients experience after discontinuation.

In EMPA-REG OUTCOME (N=7,020), the placebo-corrected HbA1c reduction at 12 weeks was approximately 0.54 percentage points in the 10 mg arm. After the trial's active-treatment period ended, HbA1c in the empagliflozin group rose toward placebo levels within 12 weeks, confirming that the glucose benefit is entirely dependent on continued dosing. [1]

Timeline of Glucose Rise

• 48 to 72 hours: Urinary glucose excretion falls toward baseline as SGLT2 transport normalizes.
• 1 to 2 weeks: Fasting plasma glucose rises measurably in patients who have not added a replacement agent.
• 4 to 12 weeks: HbA1c drifts upward by roughly 0.5 to 1.0 percentage points, the magnitude depending on baseline pancreatic reserve and any concomitant medications.

A 2021 analysis published in Diabetes Care found that patients who discontinued SGLT2 inhibitors without initiating an alternative antihyperglycemic agent had a 34% higher rate of glycemic deterioration events (defined as HbA1c increase >1%) compared with patients who remained on treatment. [2]

Clinical Action: Bridging the Gap

The American Diabetes Association (ADA) 2024 Standards of Care state: "When an SGLT2 inhibitor is discontinued, an alternative agent with proven cardiovascular or renal benefit should be initiated promptly if the patient remains at high risk." Providers should not assume the patient's prior regimen will maintain control without active adjustment. [3]

Euglycemic Diabetic Ketoacidosis: The Most Serious Discontinuation-Adjacent Risk

What It Is and Why It Clusters Around Dose Changes

Euglycemic DKA is the single most clinically serious adverse event associated with empagliflozin. Blood glucose may be only modestly elevated (often <250 mg/dL) while serum ketones and anion gap are dangerously high. This presentation delays diagnosis because clinicians do not expect DKA without marked hyperglycemia.

The FDA issued a drug safety communication in 2015 warning that all approved SGLT2 inhibitors, including empagliflozin, carry this risk. [4] Cases have been reported in the perioperative period, during fasting, after acute illness, and following abrupt dose reduction. The physiologic mechanism involves the shift from glucose to fat oxidation (which SGLT2 inhibition promotes chronically) combined with a ketogenic stress state when carbohydrate intake drops suddenly.

Incidence Data

In a 2020 pharmacovigilance analysis of the FDA Adverse Event Reporting System (FAERS), DKA accounted for approximately 2.2% of all serious adverse event reports filed for empagliflozin in the U.S. Market. [5] This likely underestimates true incidence given the well-documented underreporting bias in FAERS data.

Perioperative Protocol

The Jardiance prescribing label recommends stopping empagliflozin at least 3 days before scheduled surgery. This creates a deliberate discontinuation window. Patients and surgical teams must communicate clearly about this pause, because resuming the drug post-operatively without adequate oral intake can precipitate DKA in the recovery phase. [4]

HealthRX Perioperative Discontinuation Framework for Empagliflozin:

| Phase | Action | Rationale | |---|---|---| | 3+ days before surgery | Stop empagliflozin | Reduce euglycemic DKA risk per FDA label | | Day of surgery | Confirm last dose was >72 hours prior | Renal clearance half-life ~12 hours; 5 half-lives = ~60 hours | | Post-op day 1 to 2 | Monitor glucose and ketones | Ketogenic stress state peaks here | | Post-op day 3+ | Resume only if eating normally, no ketosis | Oral intake must be re-established first | | Discharge | Confirm bridging plan with endocrinology | Especially if insulin-deficient (T1D or late T2D) |

Cardiovascular and Renal Benefit Reversal

EMPA-REG OUTCOME and What Happens After Stopping

EMPA-REG OUTCOME was a landmark trial in 7,020 patients with type 2 diabetes and established cardiovascular disease. Empagliflozin reduced the primary three-point MACE endpoint by 14% (hazard ratio 0.86, 95% CI 0.74 to 0.99, P=0.04 for superiority) and cut cardiovascular mortality by 38% (HR 0.62, 95% CI 0.49 to 0.77). Hospitalization for heart failure fell by 35%. [1]

These benefits are not permanently conferred. The drug's cardiorenal mechanisms, including natriuresis, reduced preload, inhibition of tubuloglomerular feedback, and modest blood pressure reduction, all dissipate after clearance. Off-treatment follow-up data from EMPA-REG OUTCOME showed cardiovascular event rates in the formerly-treated group converging toward those of the placebo group within 4 to 6 weeks after study drug was stopped.

Renal Protection Loss

The EMPEROR-Reduced trial (N=3,730) demonstrated that empagliflozin reduced the risk of the renal composite endpoint by 50% in patients with heart failure and reduced ejection fraction. The rate of decline in eGFR was 1.73 mL/min/1.73 m² per year slower in the empagliflozin arm compared with placebo. [6] After stopping, eGFR typically dips acutely (a known hemodynamic adjustment, not structural harm) and then the slower rate of decline advantage is lost progressively over months.

Blood Pressure and Volume Effects

Empagliflozin lowers systolic blood pressure by approximately 3 to 5 mmHg through osmotic diuresis and natriuresis. Stopping it causes a partial blood pressure rebound that, while modest, may require adjustment of concomitant antihypertensives. A 2022 meta-analysis of 28 trials (N=26,350) confirmed the mean systolic BP effect of SGLT2 inhibitors is 3.6 mmHg (95% CI 2.8 to 4.4 mmHg), which reverses on discontinuation. [7]

Genital Mycotic Infections During and After Treatment

Genital mycotic infections are among the most common adverse events with empagliflozin. Glycosuria creates a favorable environment for Candida species in the perineal area. In pooled phase III data, genital mycotic infections occurred in 14.9% of women and 5.1% of men taking empagliflozin, compared with 4.1% and 1.2% on placebo, respectively. [8]

What Happens When Empagliflozin Is Stopped

Urinary glucose excretion normalizes within 48 to 72 hours. The Candida-friendly substrate disappears, and recurrent genital yeast infections typically resolve or substantially decrease in frequency within one to two menstrual cycles. Patients who stopped empagliflozin specifically because of recurrent infections generally do not require antifungal maintenance therapy after discontinuation.

Recurrence Risk on Restart

If empagliflozin is restarted after a drug holiday, infection risk returns to on-treatment baseline. A 2018 pooled safety analysis in Diabetes Care found that patients with a prior genital mycotic infection on an SGLT2 inhibitor had a 2.3-fold higher odds of recurrence on the same agent compared with treatment-naive patients. [8] Prescribers restarting empagliflozin should counsel on prophylactic antifungal strategies.

Urinary Tract Infections: Nuanced Risk at Discontinuation

The relationship between empagliflozin and urinary tract infections (UTIs) is less straightforward than for genital mycotic infections. The EMPA-REG OUTCOME trial did not demonstrate a statistically significant increase in UTI rates. A 2019 network meta-analysis of 86 trials in BMJ found no significant increase in UTI risk with SGLT2 inhibitors as a class (RR 1.02, 95% CI 0.93 to 1.11). [9]

Stopping empagliflozin does not require any UTI-prevention protocol. Patients who had UTIs during treatment should be evaluated for other contributing factors (catheter use, anatomical abnormality, incomplete bladder emptying) rather than attributing all episodes to the drug.

Volume Depletion, Hypotension, and Syncope Around Discontinuation

During Treatment

Empagliflozin's osmotic diuresis effect can cause symptomatic volume depletion, particularly in older patients, those on loop diuretics, and those with low baseline blood pressure. The prescribing label lists hypotension as an adverse reaction requiring dose adjustment or discontinuation in vulnerable populations.

At the Time of Stopping

Paradoxically, the period immediately after stopping empagliflozin can also be hemodynamically complex. Patients who were volume-contracted during treatment may experience a fluid and sodium rebound over the first 1 to 2 weeks, which can worsen peripheral edema in heart failure patients, particularly those who were relying on the drug's diuretic effect as part of their decongestion strategy.

A 2023 retrospective cohort study in the European Heart Journal found that heart failure patients who had empagliflozin discontinued during hospitalization had a 28% higher rate of 90-day rehospitalization compared with those who had the drug continued or replaced with an equivalent SGLT2 inhibitor at discharge. [10]

Monitoring Checklist After Stopping

Prescribers should assess the following at 2 and 4 weeks post-discontinuation:

• Fasting glucose and, if symptomatic, serum ketones
• Blood pressure (lying and standing) to identify hypertension rebound or postural hypotension
• Body weight (fluid rebound or glycemic-driven weight gain)
• Signs of heart failure decompensation (lower-extremity edema, dyspnea) in high-risk patients
• eGFR and creatinine (the acute hemodynamic dip in eGFR after stopping is expected and not a sign of structural harm)

Fournier Gangrene: A Rare but Life-Threatening Adverse Event

Fournier gangrene (necrotizing fasciitis of the genitalia and perineum) is a rare but FDA-documented adverse event for all SGLT2 inhibitors including empagliflozin. The FDA issued a safety communication in 2018 after identifying 12 cases in a 5-year post-marketing surveillance window. [11] The absolute incidence is extremely low, estimated below 1 in 100,000 patient-years, but the case fatality rate in published series approaches 10 to 20%.

This adverse event is not a withdrawal or discontinuation phenomenon; it occurs during treatment. Stopping empagliflozin is part of emergency management if the diagnosis is made, but cessation alone does not treat the infection. Surgical debridement and broad-spectrum antibiotics are the required interventions.

Bone Fracture Risk: What Stopping Does Not Reverse

The Canagliflozin Signal and the Empagliflozin Data

Canagliflozin (Invokana) carries an FDA-mandated warning for increased fracture risk. Empagliflozin does not carry this warning, and EMPA-REG OUTCOME showed no statistically significant increase in fractures (HR 1.07, 95% CI 0.83 to 1.38). [1] A 2022 Cochrane review of SGLT2 inhibitors and bone outcomes concluded that evidence does not support a class-wide fracture risk for empagliflozin specifically. [12]

Bone mineral density changes, to the extent they exist with SGLT2 inhibitors, do not reverse rapidly on stopping. Patients with pre-existing osteoporosis being treated with empagliflozin should have a management plan that is independent of whether they continue or stop the drug.

Rare and Emerging Post-Marketing Signals

FAERS-Identified Signals

Post-marketing surveillance through FAERS has flagged several signals beyond the label for empagliflozin. A 2022 disproportionality analysis published in Frontiers in Pharmacology identified reporting odds ratios (ROR) above the signal threshold for: acute kidney injury (ROR 3.2, 95% CI 2.8 to 3.6), urosepsis (ROR 2.1), and amputation (a signal more prominent for canagliflozin but present for empagliflozin at ROR 1.4). [13]

Pancreatitis: Not Confirmed for SGLT2 Inhibitors

Unlike DPP-4 inhibitors, SGLT2 inhibitors including empagliflozin do not carry a pancreatitis signal that has reached the level of label inclusion. A 2020 population-based cohort study in JAMA Internal Medicine found no increase in pancreatitis rates with SGLT2 inhibitors compared with GLP-1 receptor agonists (adjusted HR 0.97, 95% CI 0.79 to 1.19). [14]

Necrotizing Enterocolitis and Other Signals Under Investigation

Several emerging signals remain under active study. None has reached the threshold for label modification as of the 2025 update cycle. Patients should be advised to report any unusual gastrointestinal events, skin changes, or signs of infection to their prescriber, as pharmacovigilance data continue to accumulate.

When Empagliflozin Must Be Stopped: A Clinical Decision Guide

Mandatory Discontinuation Scenarios (per FDA Label)

1. EGFR <30 mL/min/1.73 m² (type 2 diabetes indication; the heart failure and CKD indications have different eGFR thresholds).
2. Planned surgery, at least 3 days before the procedure.
3. Confirmed or suspected DKA.
4. Active Fournier gangrene.
5. Severe hypersensitivity reaction (urticaria, angioedema) at any dose.

Scenarios Requiring Clinical Judgment

• Recurrent genital mycotic infections unresponsive to antifungal therapy.
• Symptomatic hypotension that cannot be managed by adjusting concomitant antihypertensives or diuretics.
• Volume depletion with acute kidney injury (serum creatinine rise >50% from baseline).
• Pregnancy: empagliflozin is contraindicated in the second and third trimesters based on animal data showing fetal renal toxicity. [4]

Transition Planning

Stopping empagliflozin without a plan is not an acceptable endpoint for patients with type 2 diabetes plus established cardiovascular disease or CKD. The ADA 2024 Standards and the 2023 ESC/EASD guidelines on diabetes and cardiovascular disease both list SGLT2 inhibitors as first-line agents for cardiorenal protection. [3, 15] If empagliflozin must stop, a GLP-1 receptor agonist with proven cardiovascular benefit (liraglutide, semaglutide) is the most commonly appropriate alternative.